The European Medicines Agency's head of vaccination strategy said on Tuesday that the agency will decide in the next days whether to start a rolling review of Merck's experimental COVID-19 tablet.Merck | Home

Interim findings released last week suggested that an experimental antiviral tablet produced by Merck & Co could reduce the risk of dying or being hospitalised for individuals most at risk of getting severe COVID-19.

When asked about Merck's medicine, Marco Cavaleri, the EMA's head of vaccination strategy, told reporters that "We will be considering whether to start a rolling review for this compound in the next days. And of course, the idea is to understand if the data supports such (a) rolling review,"